Flags

Financial distress

Solesence

NAQ:SLSN · US6300791018

ChemicalsSmall

360

Medium confidence — indicative

Value43

Profit price95

Cash yield1

Owner Earnings Yield1

Dividend Yield1

Sales & asset price39

Price/Sales69

EV / Gross Profit23

Price/Book24

Quality30

Returns on capital35

Return on Capital28

Cash Return on Capital27

Return on Equity50

Profit margins54

EBIT Margin22

Gross Profitability86

Cash backing17

Cash Conversion10

Accruals12

Owner Earnings Margin28

Growth17

Sales growth13

Profit growth12

Profit Growth11

Long-Term EPS Growth17

Owner Earnings Growth9

Reinvestment85

Price momentum1

Safety21

Debt load22

Debt serviceability46

Refinancing91

Debt Payback1

Liquidity33

Sentiment50

Analyst ratings—

Expectations trend—

Market mood7

Value Creation2/20not creating value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Solesence doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA

IndustryChemicals

SizeSmall

TypePublic Company

ExchangeNASDAQCM

Founded1989

Employees36

Websiteir.solesence.com

ISINUS6300791018

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

CleanTechHealth DiagnosticsLifestyleDermatologyNanotechnology

Description

Solesence, Inc. operates as a science-driven company focused on various beauty and life-science markets. The company's business is primarily driven by consumer health as the end goal, with science and innovation guiding its path. Skin health and med…

Analysis

Weak and unloved

Solesence, Inc. is weak and unloved: below-average business metrics and a price that reflects that disappointment. One caution: reported profits have recently run ahead of actual cash, which we track closely.

Valuation data is not available for this company.

The trajectory is weak and the balance sheet is fragile. The company scores 2/20 on our value-creation score: not creating value.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Solesence with its peers

Becton Dickinson

NYQ:BDX

CountryUSA

IndustryHealth Care Equipment & Supplies

SizeXX-Large

Full Stock Analysis →

Fate Therapeutics

NMQ:FATE

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Balchem

NSQ:BCPC

CountryUSA

IndustryChemicals

SizeMedium

Full Stock Analysis →

Avient

NYQ:AVNT

CountryUSA

IndustryChemicals

SizeLarge

Full Stock Analysis →

Metagenomi Therapeutics

NSQ:MGX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Sotera Health

NSQ:SHC

CountryUSA

IndustryLife Sciences Tools & Services

SizeLarge

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →